Venture Capital Growth In Orphan Drugs Aided By ‘Regulatory Certainty’
Executive Summary
Investment funds seeking greater clarity around regulatory and reimbursement issues increasingly are turning away from chronic disease drug development in favor of new treatments for rare diseases, according to two studies.